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Background: Cases of primary gastric adenocarcinoma with metastasis to the breast are extremely rare. Till now,
only 38 cases have been reported in PubMed since 1908.
Case presentation: We herein reported a race case of gastric adenocarcinoma with metastasis to the right breast.
Breast biopsy showed invasive signet-ring cell breast carcinoma in the right breast. She was given a TEC regimen
(docetaxel 75 mg/m2, epirubicin 75 mg/m2, and cyclophosphamide 600 mg/m2 every 3 weeks) for one cycle but
showed no objective response. Upper gastrointestinal endoscopy demonstrated an ulcerative mass in the gastric
body. Biopsy demonstrated low-grade gastric adenocarcinoma with signet-ring features. In immunohistochemistry,
mammary malignant cells were positive for cytokeratin 7, cytokeratin 20, villin, and ErbB2/HER2, but negative for
gross cystic disease fluid protein-15, estrogen receptor, and progesterone receptor. The diagnosis of metastatic
poorly differentiated signet-ring cell adenocarcinoma of the right breast identical to gastric primary was confirmed
finally.
Conclusions: Gastric cancer with metastasis to the breast can be diagnosed by clinical history, histological findings,
and immunohistochemical markers.
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Gastric carcinoma with metastasis to the breast is
extremely rare. Only 38 cases have been reported in
PubMed thus far. The lymph node dissemination might
be the possible mechanism of metastasis from the stom-
ach to the breast. Sometimes, a metastatic tumor in an
occult site may be difficult to be distinguished be-
tween a synchronous or metachronous primary cancer
and a metastatic disease, especially when it is asymptom-
atic. In this study, we reported a case of a 48-year-old
Chinese woman with a metastasis to the right breast from
a gastric signet-ring cell carcinoma and reviewed the
literature.Case presentation
A 48-year-old Chinese woman was admitted to the Subei
People’s Hospital of Jiangsu Province, China, on 29 July* Correspondence: chen86ky@126.com
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Physical examination showed an 8.0-cm × 5.0-cm mass
lying in the upper inner quadrant of the right breast
with axillary lymphadenopathy on both sides. The
ultrasound showed an 8.9-cm × 4.7-cm ill-defined le-
sion in the upper inner quadrant of the right breast
and a 1.8-cm × 1.2-cm enlarged lymph node in the
right axilla (Figure 1A,B). Core needle biopsy showed
invasive signet-ring cell breast carcinoma (Figure 2A).
Immunohistochemistry (IHC) showed that tumor cells
were positive for epidermal growth factor receptor
(EGFR) and ErbB2/HER2, but negative for estrogen re-
ceptor (ER) and progesterone receptor (PR). Serum
tumor markers including carcinoembryonic antigen
(CEA), cancer antigen (CA) 153, CA125, and CA199
did not elevate. A TEC regimen (docetaxel 75 mg/m2,
epirubicin 75 mg/m2, and cyclophosphamide 600 mg/
m2 every 3 weeks) was administered as neoadjuvant
chemotherapy.is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Ultrasonography of the breast. In 30 July 2014, ultrasonography revealed an 88.7-mm × 47.0-mm ill-defined heterogeneity
lesion (arrow) in the upper inner quadrant of the right breast (A) with right enlarged axillary lymph nodes (arrow), 17.9 mm × 12.4 mm in
diameter (B). In 21 August 2014, ultrasonography revealed a 94.3-mm × 63.6-mm ill-defined heterogeneity lesion (arrow) in the upper
inner quadrant of the right breast (C) with right enlarged axillary lymph nodes (arrow), 25.9 mm × 11.4 mm in diameter (D).
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raphy was performed and showed an increased 9.4-cm ×
6.4-cm ill-defined hypoechoic mass in the upper inner
quadrant as well as a 2.6-cm × 1.1-cm enlarged lymph
node in the right axilla on 21 August 2014 (Figure 1C,D).
Enhanced abdominal computed tomography (CT) re-
vealed a circumferential mural thickening of the gastric
body wall (Figure 3C). Upper gastrointestinal endoscopy
demonstrated an ulcerative mass in the gastric body
(Figure 3A,B). Biopsy of the lesion revealed infiltration
from a diffuse-type low-grade gastric adenocarcinoma
with signet-ring features (Figure 2B). Serum tumor
markers including CEA, CA153, CA125, and CA199 weremeasured, and only CA199 was highly elevated (more than
1000 IU/mL). Further immunohistochemistry showed the
tumor was positive for cytokeratin 7 (CK7), CK20, villin,
and ErbB2/HER2, but negative for gross cystic disease
fluid protein-15 (GCDFP-15), ER, and PR (Figure 2C,D,E,
F,G,H,I and Table 1). These features helped to make
the diagnosis of primary gastric adenocarcinoma with
metastasis to the right breast. Then, the patient was
treated with SOX regimen for four cycles (S-1 80 mg/m2,
oxaliplatin 100 mg/m2). At time of submission of our
manuscript, the patient responded well to the adjusted
chemotherapy and was followed for 4 months after the
definite diagnosis was made.
Figure 2 Breast and gastric biopsy and immunohistochemical analysis. Breast biopsy showed invasive carcinoma with signet-ring cells
(hematoxylin and eosin, magnification × 100) (A). Gastric biopsy showed infiltration from a diffuse-type low-grade gastric adenocarcinoma
with signet-ring features (hematoxylin and eosin, magnification × 100) (B). Immunohistochemical analysis revealed mammary tumor cells
were positive for ErbB2/HER2 (C), CK7 (D), CK20 (E), and villin (F), but negative for ER (G), PR (H), and GCDFP-15 (I) (3,3′-diaminobenzidine,
magnification × 100).
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Metastases from extra-mammary malignant neoplasms
are rare, constituting only 0.5% to 2.0% of all mammary
malignancies [1]. Malignant melanoma, lymphoma, lung
cancer, ovarian cancer, and soft tissue sarcoma have been
reported as the most common original tumor of mam-
mary metastases. Gastrointestinal and genitourinary
tumors are less common primary sites. Sporadic cases
of mammary metastasis have been reported from osteo-
sarcoma, thyroid neoplasm, and cervical, vaginal, and
endometrial carcinoma [2-6].
Since primary gastric adenocarcinoma with metasta-
sis to the breast is extremely rare, PubMed, MED-
LINE, Embase, and Google Scholar were searched till
September 2014 using the key words such as “gastric
or stomach”; “tumor or cancer or carcinoma or ad-
enocarcinoma”; “breast or mammary”; and “metasta-
sis.” Only 38 cases have been reported previously. We
made a summary of all these 38 cases as well as the
present case to highlight their clinicopathological
characteristics (Table 2). The age of these patients
ranged from 23 to 70 years (mean 46.5 years; median
46 years). Among 36 cases, 22 harbored a histological
feature of signet-ring cell adenocarcinoma. Moreover,multiple metastases could be found in these cases ex-
cept the breast.
Metastatic mammary carcinoma is usually correlated
with a poor prognosis. Based on the previous reported
cases, the overall survival lasted from 12 days to
18 months. In the metastatic process, mammary involve-
ment could either be the first station or occur in a poly-
metastatic context [7]. Although the pathway by which
malignancies metastasized to the breast remains un-
known, Vergier et al. [8] hypothesized that estrogen may
play a role in promoting extra-mammary tumorigenesis.
Also, abundant blood supply of the breast has been pro-
posed as the mechanism for the increased incidence of
breast metastasis in premenopausal women. On the
other hand, the metastases from gastric carcinoma to
the breast had a surprisingly unified tendency. The left
breast involved accounted for 55.9% (19/34) of all cases,
while the right side accounted for 23.5% (8/34) and
both sides 20.6% (7/34). Accordingly, Parrell et al. [9]
reported that breast metastases were most commonly
found in the upper outer quadrant of the left side.
This phenomenon suggested the left supraclavicular
lymph node might be important in the process of me-
tastasis from gastric carcinoma to the breast. Occult
Figure 3 Gastric endoscopy and enhanced abdominal CT scan. Gastric endoscopy showed an ulcerative mass in the gastric body (arrows)
(A,B). Enhanced abdominal CT scan revealed a circumferential mural thickening of the gastric body wall (arrows) (C).
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and pathologists and may lead to an absolutely differ-
ent therapeutic strategy. Histopathology is useful to
differentiate mammary metastasis from primary breast
cancer [10]. IHC remains the main choice in identifyingTable 1 Immunohistochemical analysis of mammary
tumor cells
Antibodies P/N Antibodies P/N
CK7 + GST-Π ++
CK20 + Ki-67 labeling index 60%
EGFR + PR −
ER − P-gp −
ErbB2/HER-2 + TOPO-II ++
GCDFP-15 − Villin +
P/N: positive/negative; CK: cytokeratin; EGFR: epidermal growth factor
receptor; ER: estrogen receptor; ErbB2/HER-2: human epidermal growth factor
receptor 2; GCDFP-15: gross cystic disease fluid protein-15; GST-Π: glutathione
S transferases Π; PR: progesterone receptor; P-gp: P-glycoprotein; TOPO-II:
topoisomerase II; −: no cells positive by IHC; ±: sometimes weak positive,
sometimes negative by IHC; +: <25% of cells positive by IHC; ++: 25%–50% of
cells positive by IHC; +++: >50% of cells positive by IHC.the tumor origin. Although only few of tumor markers
are very specific with limited sensitivity, they can be
used as a panel to improve the sensitivity. IHC stain-
ing for breast metastasis from gastric cancer is usually
negative for ErbB-2, ER, PR, and GCDFP-15, but
positive for epithelial markers like CEA, CK7, and
CK20 [11-13].Conclusions
A primary gastric adenocarcinoma with metastasis to
the breast is an extremely rare malignancy and is usually
associated with poor prognosis. Clinical history, histo-
logical findings, and immunohistochemical markers such
as CK20, CK7, CDX-2, villin, and GCDFP-15 are helpful
in distinguishing primary breast cancer from breast me-
tastasis of gastric cancer.Consent
Written informed consent was obtained from the
patient.
Table 2 Clinicopathological features of reported cases of primary gastric carcinoma with breast metastasis
Case [ref] Age Side Differentiation Interval (mo) Other metastases Follow-up (mo)
Reitmann et al. 1908a 33 R + L Scirrhous – – –
Kreibich et al. 1909a 65 R Scirrhous – Skin –
Mourier et al. 1910a 31 L Mucinous – Liver and pancreas –
Stahr et al. 1922a 46 R + L Anaplastic – – –
Dawson et al. 1936a 25 R + L Mucinous – Ovaries –
Abrams et al. 1949a – – – – – –
Sandison et al. 1959a 56 L Signet-ring cell – – –
[14] 59 R + L – 4 Axillary lymphadenopathy 6
Hajdu et al. 1972a – L Adenocarcinoma – – –
Silverman et al. 1974 [15] – – Mucin-producing 0 – –
Toombs et al. 1977a – – – – – –
Satake et al. 1980a 39 L Signet-ring cell 0 – –
Togo et al. 1980a 70 L Signet-ring cell 0 – –
Nielsen et al. 1981a 59 L Mucinous 0 – –
Champault et al. 1982a 65 L Adenocarcinoma 0 – –
[16] 46 L Signet-ring cell 0 Axillary lymphadenopathy 12 days
Kasuga et al. 1986a 48 R + L Signet-ring cell 31 – –
[17] 28 R + L Mucinous differentiation 0 Lymph nodes –
[18] 31 R Signet-ring cell 0 Lymph nodes, ovaries –
[19] 36 L Poorly with signet-ring cells 72 Axillary lymphadenopathy 3
[20] – – Signet-ring cell – – –
Domanski et al. 1996 [21] 48 L Signet-ring cell 0 Left supraclavicular nodes –
de la Cruz Mera et al. 1998 [22] 61 L Signet-ring cell 13 Pleura –
[23] 46 R + L Signet-ring cell 2 Bilateral axillary nodes –
[24] 41 L Signet-ring cell 0 Ovaries –
[24] 23 R Signet-ring cell 0 Axillary nodes –
Madan et al. 2002 [10] 39 R Signet-ring cell 3 Ovaries, peritoneum –
[25] 39 R + L Signet-ring cell 1 Ovaries, peritoneum, skin –
Boutis et al. 2005 [12] 37 L Signet-ring cell 0 Ovaries 6
[26] 37 L Poorly 0 – 6
[27] 61 R Poorly 48 Peritoneum 2
Makni et al. 2007 [7] 40 R Signet-ring cell 4 Ovaries, spleen 18
[11] 67 L Poorly with signet-ring cells 5 Left axillary and supraclavicular nodes 4
Cil et al. 2009 [28] 63 L Signet-ring cell 12 Left axillary nodes 4
Cil et al. 2009 [28] 65 L Signet-ring cell 24 Right ovarian, liver and lung 6
Soler et al. 2010 [9] 37 L Signet-ring cell 2 Ovarian 7
[29] 37 L Signet-ring cell 31 - -
[30] 54 R Signet-ring cell 0 Right ovarian 11
This case 48 R Signet-ring cell 0 Right axillary nodes 2 alive
aReferences are included in [18]. Interval: the time between the diagnosis of gastric carcinoma and the development of metastasis to the breast; mo, month;
Poorly: poorly differentiated adenocarcinoma; Signet-ring cell: signet-ring cell carcinoma.
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